195 related articles for article (PubMed ID: 18715779)
21. Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy.
Drygin D; Haddach M; Pierre F; Ryckman DM
J Med Chem; 2012 Oct; 55(19):8199-208. PubMed ID: 22924342
[No Abstract] [Full Text] [Related]
22. Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia.
Bellon M; Lu L; Nicot C
Blood; 2016 May; 127(20):2439-50. PubMed ID: 26813676
[TBL] [Abstract][Full Text] [Related]
23. Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia.
Narlik-Grassow M; Blanco-Aparicio C; Cecilia Y; Perez M; Muñoz-Galvan S; Cañamero M; Renner O; Carnero A
PLoS One; 2013; 8(4):e60277. PubMed ID: 23565217
[TBL] [Abstract][Full Text] [Related]
24. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.
Holder S; Zemskova M; Zhang C; Tabrizizad M; Bremer R; Neidigh JW; Lilly MB
Mol Cancer Ther; 2007 Jan; 6(1):163-72. PubMed ID: 17218638
[TBL] [Abstract][Full Text] [Related]
25. Cdc7 as a potential new target for cancer therapy.
Ito S; Taniyami C; Arai N; Masai H
Drug News Perspect; 2008 Nov; 21(9):481-8. PubMed ID: 19180266
[TBL] [Abstract][Full Text] [Related]
26. Regulation of prostate stromal fibroblasts by the PIM1 protein kinase.
Zemskova MY; Song JH; Cen B; Cerda-Infante J; Montecinos VP; Kraft AS
Cell Signal; 2015 Jan; 27(1):135-46. PubMed ID: 25451079
[TBL] [Abstract][Full Text] [Related]
27. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
Pang B; Zhang H; Wang J; Chen WZ; Li SH; Shi QG; Liang RX; Xie BX; Wu RQ; Qian XL; Yu L; Li QM; Huang CF; Zhou JG
Prostate; 2009 Aug; 69(11):1176-87. PubMed ID: 19415690
[TBL] [Abstract][Full Text] [Related]
28. Targeting the RAF-MEK-ERK pathway in cancer therapy.
Montagut C; Settleman J
Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
[TBL] [Abstract][Full Text] [Related]
29. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
Santarpia L; Ye L; Gagel RF
J Intern Med; 2009 Jul; 266(1):99-113. PubMed ID: 19522829
[TBL] [Abstract][Full Text] [Related]
30. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma.
Wang J; Kim J; Roh M; Franco OE; Hayward SW; Wills ML; Abdulkadir SA
Oncogene; 2010 Apr; 29(17):2477-87. PubMed ID: 20140016
[TBL] [Abstract][Full Text] [Related]
31. Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells.
Ummanni R; Teller S; Junker H; Zimmermann U; Venz S; Scharf C; Giebel J; Walther R
FEBS J; 2008 Nov; 275(22):5703-13. PubMed ID: 18959755
[TBL] [Abstract][Full Text] [Related]
32. Clinical and therapeutic relevance of PIM1 kinase in gastric cancer.
Yan B; Yau EX; Samanta S; Ong CW; Yong KJ; Ng LK; Bhattacharya B; Lim KH; Soong R; Yeoh KG; Deng N; Tan P; Lam Y; Salto-Tellez M;
Gastric Cancer; 2012 Apr; 15(2):188-97. PubMed ID: 21993851
[TBL] [Abstract][Full Text] [Related]
33. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling.
Kojima T; Shimazui T; Hinotsu S; Joraku A; Oikawa T; Kawai K; Horie R; Suzuki H; Nagashima R; Yoshikawa K; Michiue T; Asashima M; Akaza H; Uchida K
Oncogene; 2009 Jan; 28(2):297-305. PubMed ID: 18931698
[TBL] [Abstract][Full Text] [Related]
34. Phytoconstituents and Medicinal Plants for Anticancer Drug Discovery: Computational Identification of Potent Inhibitors of PIM1 Kinase.
Anjum F; Mohammad T; Almalki AA; Akhtar O; Abdullaev B; Hassan MI
OMICS; 2021 Sep; 25(9):580-590. PubMed ID: 34448628
[TBL] [Abstract][Full Text] [Related]
35. High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients.
Wang Z; Cai SR; He YL; Zhan WH; Chen CQ; Cui J; Wu WH; Wu H; Song W; Zhang CH; Peng JJ; Huang XH
Ann Surg Oncol; 2009 Jan; 16(1):208-19. PubMed ID: 19009246
[TBL] [Abstract][Full Text] [Related]
36. Crystal structure of pim1 kinase in complex with a pyrido[4,3-d]pyrimidine derivative suggests a unique binding mode.
Lee SJ; Han BG; Cho JW; Choi JS; Lee J; Song HJ; Koh JS; Lee BI
PLoS One; 2013; 8(7):e70358. PubMed ID: 23936194
[TBL] [Abstract][Full Text] [Related]
37. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
38. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.
Tao ZF; Hasvold LA; Leverson JD; Han EK; Guan R; Johnson EF; Stoll VS; Stewart KD; Stamper G; Soni N; Bouska JJ; Luo Y; Sowin TJ; Lin NH; Giranda VS; Rosenberg SH; Penning TD
J Med Chem; 2009 Nov; 52(21):6621-36. PubMed ID: 19842661
[TBL] [Abstract][Full Text] [Related]
39. Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors.
Bogusz J; Zrubek K; Rembacz KP; Grudnik P; Golik P; Romanowska M; Wladyka B; Dubin G
Sci Rep; 2017 Oct; 7(1):13399. PubMed ID: 29042609
[TBL] [Abstract][Full Text] [Related]
40. High Expression of NEK2 and PIM1, but Not PIM3, Is Linked to an Aggressive Phenotype of Bronchopulmonary Neuroendocrine Neoplasms.
Motylewska E; Braun M; Stępień H
Endocr Pathol; 2020 Sep; 31(3):264-273. PubMed ID: 32504181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
